Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Can the Serum Level of Myostatin be Considered as an Informative Factor for Cachexia Prevention in Patients with Medullary Thyroid Cancer?

  • Hedayati, Mehdi (Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences) ;
  • Nozhat, Zahra (Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences) ;
  • Hannani, Masoomeh (Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences)
  • Published : 2016.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Thyroid cancer, the most common endocrine neoplasia, consists of four main types of carcinomas: papillary, follicular, and anaplastic, all with thyroid follicular origin, and medullary thyroid cancer (MTC) related to para-follicular cells. Cronic diseases such as diverse cancers may be associated with cachexia, especially at advanced stage. Cancer-induced cachexia is associated with diminished quality of life, functional performance, reduced response to antitumor therapy, and increased morbidity and mortality. Myostatin (Mst) is one of the outstanding molecules in the skeletal muscle loss process in cancer and it may be released by both skeletal muscle and cachexia-inducing tumors. Recently changes in serum levels of Mst have been identified as an important factor of cancer-induced cachexia. The goal of this study was to assessserum Mst levels in MTC patients. In this descriptive and case-control study, 90 participants were selected, comprising 45 MTC patients (20 males, $29{\pm}13.9years$, 25 females, $29{\pm}14.5years$) and 45 control individuals (25 males, $23.1{\pm}11.6years$, 20 females, $31.5{\pm}14.4years$). Serum Mst was determined using an ELISA kit and body mass index (BMI) was calculated by weight and height measurements. The Kolmogorov Simonov test showed a normal distribution for log transformed Mst serum levels in both case and control groups. Geometric means were 5.9 and 8.2 ng/ml respectively, and a significant difference was found according to the independent t-test results (P<0.01). There was also a significant difference mean of Mst between females in control and MTC groups, but not for the males. Pearson correlation test showed no correlation between age and BMI with Mst serum levels. The findings of this study support the hypothesis that Mst serum levels may have a potential ability for early diagnosis of cachexia in MTC patients, especially in females.

Keywords

References

  1. Alvandi E, Akrami SM, Chiani M, et al (2011). Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population. Thyroid, 21, 373-82. https://doi.org/10.1089/thy.2010.0267
  2. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ, (2014). Cancer cachexia: understanding the molecular basis. Nat Rev Cancer, 14, 754-62. https://doi.org/10.1038/nrc3829
  3. Aversa Z, Bonetto A, Penna F, et al (2012). Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol,19, 1350-6. https://doi.org/10.1245/s10434-011-1720-5
  4. Baracos VE, (2013). Clinical Trials of Cancer Cachexia Therapy, Now and Hereafter. J Clin Oncol, 31, 1257-8. https://doi.org/10.1200/JCO.2012.48.3149
  5. Bonetto A, Penna F, Aversa Z, et al (2013). Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients. Muscle Nerve, 48, 387-92. https://doi.org/10.1002/mus.23798
  6. Breitbart A, Scharf GM, Duncker D et al, (2013). Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. Plos One, 8, e80454-9. https://doi.org/10.1371/journal.pone.0080454
  7. Carneiro I, Castro-Piedras I, Munoz A, et al (2008). Hypothyroidism is associated with increased myostatin expression in rats. J Endocrinol Invest, 31, 773-8. https://doi.org/10.1007/BF03349256
  8. Ceolin L, Siqueira DR, Romitti M, Ferreira CV, Maia AL (2012). Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms. Int J Mol Sci, 13, 221-39.
  9. Cho YA, Kong SY, Shin A, et al (2014). Biomarkers of thyroid function and autoimmunity for predicting high-risk groups of thyroid cancer: a nested case-control study. BMC cancer, 14, 873. https://doi.org/10.1186/1471-2407-14-873
  10. Donohoe CL, Ryan AM, Reynolds JV, (2011). Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract, 2011,60143-4
  11. Elkina Y, von Haehling S, Anker SD, Springer J, (2011). The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle, 2, 143-51. https://doi.org/10.1007/s13539-011-0035-5
  12. Evans WJ, Morley JE, Argiles J, et al (2008). Cachexia: a new definition. Clin Nutr, 27, 793-9. https://doi.org/10.1016/j.clnu.2008.06.013
  13. Ghazi AA, Bagheri M, Tabibi A, Sarvghadi F, et al (2014). Multiple endocrine neoplasia type 2A in an Iranian family: clinical and genetic studies. Arch Iran Med, 17, 378-82.
  14. Hedayati M, Nabipour I, Rezaei-Ghaleh N, Azizi F (2006). Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Med J Malaysia, 61, 564-9.
  15. Hedayati M, Zarif Yeganeh M, SheikholEslami S, et al (2011). Predominant RET germline mutations in exons 10, 11, and 16 in Iranian patients with hereditary medullary thyroid carcinoma. J Thyroid Res, 2011, 26424-8.
  16. Kern KA, Norton JA, (1988). Cancer cachexia. J Parenter Enteral Nutr, 12, 286-98. https://doi.org/10.1177/0148607188012003286
  17. Lokireddy S, Wijesoma IW, Bonala S, et al, (2012). Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem J, 446, 23-36. https://doi.org/10.1042/BJ20112024
  18. Loumaye A, de Barsy M, Nachit M, et al (2015). Role of Activin A and Myostatin in human cancer cachexia. J Clin Endocrinol Metab, 100, 2030-8. https://doi.org/10.1210/jc.2014-4318
  19. Majidi M, Haghpanah V, Hedayati M, et al (2011). A family presenting with multiple endocrine neoplasia type 2B: A case report. J Med Case Rep, 5, 587-92. https://doi.org/10.1186/1752-1947-5-587
  20. McPherron AC, Lawler AM, Lee SJ, (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387, 83-90. https://doi.org/10.1038/387083a0
  21. Penet MF, Winnard PT Jr, Jacobs MA, et al (2011). Understanding cancer-induced cachexia: imaging the flame and its fuel. Curr Opin Support Palliat Care, 5, 327-33. https://doi.org/10.1097/SPC.0b013e32834c49ba
  22. Sheikholeslami S, Zarif Yeganeh M, Hoghooghi Rad L, Golab Ghadaksaz H, Hedayati M (2014). Haplotype frequency of G691S/S904S in the RET proto-onco-gene in patients with medullary thyroid carcinoma. Iran J Public Health, 43, 235-40.
  23. Shum AM, Polly P, (2012). Cancer cachexia: molecular targets and pathways for diagnosis and drug intervention. Endocr Metab Immune Disord Drug Targets, 12, 247-59. https://doi.org/10.2174/187153012802002910
  24. Smith RC, Lin BK, (2013). Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care, 7, 352-60. https://doi.org/10.1097/SPC.0000000000000013
  25. Tisdale MJ, (2009). Mechanisms of cancer cachexia. Physiol Rev, 89, 381-410. https://doi.org/10.1152/physrev.00016.2008
  26. Zarif Yeganeh M, Sheikholeslami S, Dehbashi Behbahani G, Farashi S, Hedayati M (2105). Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma. Tumour Biol, 36, 5225-31. https://doi.org/10.1007/s13277-015-3179-7
  27. Zarif-Yeganeh M, Sheikholeslami S, Dehbashi-Behbahani G, et al (2015). Point Mutations in RET Proto-Oncogene Exon 10 in Patients with Medullary Thyroid Carcinoma. J Kerman Univ Med Sci, 22, 249-60.

Cited by

  1. Evaluation of Serum Vascular Adhesion Protein-1 as a Potential Biomarker in Thyroid Cancer vol.2016, pp.1687-8345, 2016, https://doi.org/10.1155/2016/6312529